CUNNINGHAM SEAN LAURENCE 4
4 · MARAVAI LIFESCIENCES HOLDINGS, INC. · Filed May 28, 2026
Research Summary
AI-generated summary of this filing
Maravai (MRVI) Director Sean Cunningham Receives RSU Award
What Happened
Sean Laurence Cunningham, a director of Maravai LifeSciences Holdings, Inc. (MRVI), received an award of 46,293 restricted stock units (RSUs) on May 26, 2026. The RSUs were granted at $0.00 per share (standard for restricted awards) and therefore have no immediate cash purchase value. Per the grant terms, the RSUs vest in full upon the earlier of one year from the grant date or the 2027 Maravai annual meeting of stockholders.
Key Details
- Transaction date: 2026-05-26; Form 4 filed: 2026-05-28 (filed timely).
- Security: 46,293 restricted stock units (RSUs); reported acquisition price: $0.00; total reported value at grant: $0.
- Vesting: RSUs vest in full upon the earlier of one year from grant or the 2027 annual meeting (footnote F1).
- Beneficial ownership note: Reporting person holds these securities for the benefit of a GTCR‑affiliated entity and disclaims pecuniary interest (footnote F2).
- Shares owned after transaction: not specified in the provided excerpt of the filing.
Context
RSUs are compensation awards that convert into actual shares only after vesting; they are not an outright purchase or sale and do not by themselves signal a buy/sell decision. The F2 disclosure indicates these RSUs are held for a GTCR‑affiliated entity (an institutional/private equity interest), so this report reflects an award tied to that relationship rather than a personal open‑market trade.
Insider Transaction Report
- Award
Class A Common Stock
[F1][F2]2026-05-26+46,293→ 184,348 total
Footnotes (2)
- [F1]Represents restricted stock units awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan on May 26, 2026, which vest in full upon the earlier of one year from the date of grant or the date of the 2027 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders.
- [F2]The Reporting Person holds these securities of the Issuer for the benefit of a GTCR-affiliated entity. Pursuant to the policies of the GTCR-affiliated entities, the Reporting Person must hold the securities on behalf of and for the benefit of the GTCR-affiliated entity. The Reporting Person disclaims any pecuniary interest in the securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16.